title: Response to "Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is It Worth?"
authors.affiliation: Genentech, South San Francisco, California, USA.
authors.forename: I E
authors.initials: IE
authors.lastname: Templeton
authors.affiliation: Genentech, South San Francisco, California, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Genentech, South San Francisco, California, USA.
authors.forename: J
authors.initials: J
authors.lastname: Mao
authors.affiliation: Pfizer Inc., Groton, Connecticut, USA.
authors.forename: J
authors.initials: J
authors.lastname: Lin
authors.affiliation: Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA.
authors.forename: H
authors.initials: H
authors.lastname: Yu
authors.affiliation: Merck Serono, Darmstadt, Hessen, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Peters
authors.affiliation: AbbVie Inc., North Chicago, Illinois, USA.
authors.forename: M
authors.initials: M
authors.lastname: Shebley
authors.affiliation: Pfizer Inc., Groton, Connecticut, USA.
authors.forename: M V
authors.initials: MV
authors.lastname: Varma
mesh_terms: D065692:Cytochrome P-450 CYP3A Inhibitors; D004347:Drug Interactions
chemical_list: D065692:Cytochrome P-450 CYP3A Inhibitors